Summit Creek Advisors LLC Purchases 1,113 Shares of Vericel Co. (NASDAQ:VCEL)

Summit Creek Advisors LLC boosted its stake in shares of Vericel Co. (NASDAQ:VCEL) by 0.3% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 351,773 shares of the biotechnology company’s stock after buying an additional 1,113 shares during the quarter. Vericel makes up approximately 2.5% of Summit Creek Advisors LLC’s investment portfolio, making the stock its 17th biggest holding. Summit Creek Advisors LLC’s holdings in Vericel were worth $19,316,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. FMR LLC raised its holdings in Vericel by 1.0% during the 3rd quarter. FMR LLC now owns 2,372,812 shares of the biotechnology company’s stock valued at $100,251,000 after buying an additional 22,461 shares during the period. Congress Asset Management Co. raised its holdings in Vericel by 12.6% during the 4th quarter. Congress Asset Management Co. now owns 1,454,139 shares of the biotechnology company’s stock valued at $79,847,000 after buying an additional 162,419 shares during the period. GW&K Investment Management LLC raised its holdings in Vericel by 2.4% during the 4th quarter. GW&K Investment Management LLC now owns 1,273,964 shares of the biotechnology company’s stock valued at $69,953,000 after buying an additional 30,180 shares during the period. William Blair Investment Management LLC raised its holdings in Vericel by 66.3% during the 4th quarter. William Blair Investment Management LLC now owns 1,258,416 shares of the biotechnology company’s stock valued at $69,100,000 after buying an additional 501,736 shares during the period. Finally, Geode Capital Management LLC raised its holdings in Vericel by 0.8% during the 3rd quarter. Geode Capital Management LLC now owns 1,154,053 shares of the biotechnology company’s stock valued at $48,768,000 after buying an additional 9,613 shares during the period.

Insider Activity

In related news, Director Robert L. Md Zerbe sold 2,500 shares of the firm’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total transaction of $156,250.00. Following the sale, the director now owns 26,595 shares of the company’s stock, valued at $1,662,187.50. This trade represents a 8.59 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Jonathan Siegal sold 3,908 shares of the firm’s stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $61.99, for a total value of $242,256.92. Following the sale, the insider now directly owns 1,206 shares in the company, valued at approximately $74,759.94. The trade was a 76.42 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,092 shares of company stock worth $1,683,582. Company insiders own 5.20% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on VCEL shares. BTIG Research increased their price target on Vericel from $56.00 to $66.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Truist Financial reiterated a “buy” rating and issued a $61.00 target price (down previously from $67.00) on shares of Vericel in a research note on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Vericel in a research note on Friday, February 28th. Canaccord Genuity Group increased their target price on Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a research note on Monday, February 3rd. Finally, StockNews.com upgraded Vericel from a “sell” rating to a “hold” rating in a research note on Saturday, March 8th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Vericel currently has a consensus rating of “Moderate Buy” and an average price target of $62.29.

Vericel Trading Down 1.9 %

Shares of Vericel stock opened at $46.26 on Monday. The firm has a market cap of $2.31 billion, a P/E ratio of 771.13 and a beta of 1.78. Vericel Co. has a 12 month low of $39.12 and a 12 month high of $63.00. The stock’s fifty day moving average price is $54.40 and its 200-day moving average price is $51.72.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.